Emerging evidence has recently showcased the abnormal expression of METTL1 in tumor tissues and cell lines, underscoring the significant role of m7G modification in the development and progression of various cancers such as hepatocellular carcinoma (HCC) [10], head and neck squamous cell carcinoma (HNSCC) [11], oral squamous cell carcinoma [12] and osteosarcoma [13]. Here, METTL1 is linked to osteosarcoma.